Novo Nordisk's CEO, Lars Fruergaard Jørgensen, resigns amid a 50% drop in the company’s share price.

Lars Fruergaard Jørgensen, CEO of pharmaceutical company Novo Nordisk, is stepping down due to a mutual agreement with the board amid market challenges and a 50% drop in the company's share price since mid-2024. Jørgensen will continue in his role temporarily to ensure a smooth transition. The company's sales and profits have almost tripled under his eight-year tenure, but recent competition from cheaper replica drugs and rival products has impacted Wegovy sales.